-
Security Type
-
Common Stock
-
Categories
-
Technology, Healthcare & Medical
-
Min Investment
-
$250
-
Offering Date
-
January 17, 2022
-
Expected Close Date
-
July 28, 2022
-
Target Raise
-
$10.00K-$1.07M
-
No. Investors
-
82
-
Security Price
-
$2
-
Valuation
-
$26,700,000
- Number of Employees
- 4
- Cash
- $12,260
- Revenue
- $0
- Short Term Debt
- $2,552
- Cost of Goods
- $0
- Long Term Debt
- $10,210
- Net Income
- $-89,253
Company Description
The opioid crisis is an enormous problem. Over 100,000 people died from opioid overdoses between April 2020 to April 2021.* Revolution MD is developing a patent-pending smart inhaler designed to safely control the dispensing of opioids, providing immediate pain relief while minimizing the risk of addiction. Our Inhale device prevents abuse, addiction, and overdose by using real-time identity verification and communicating with prescribing physicians to ensure compliance. Become part of the solution and help us save countless lives by investing in Revolution MD’s blockchain-based technology. We’re ready to revolutionize the delivery of medication worldwide. Revolution MD is in the pre-revenue stage of development and is currently in its prototype phase, with a patent-pending.
Perks
StartEngine OWNERS Exclusive Click here to learn more
$250+ Investment
StartEngine Owner’s Bonus
This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.
$1,000+ Investment
Tier 1
Invest $1,000+ and receive 5% Bonus Shares.
$2,000+ Investment
Tier 2
Invest $2,000+ and receive 10% Bonus Shares.
$5,000+ Investment
Tier 3
Invest $5,000+ and receive 15% Bonus Shares.
$10,000+ Investment
Tier 4
Invest $10,000+ and receive 20% Bonus Shares.
Key Deal Facts
Opportunity to Invest in a Growing Biotech Market | The global biotechnology market stood at USD $627.63 Billion in 2020 and is expected to grow at a CAGR of 8.57% through 2026, while the global market for opioids was estimated at USD $25.4 Billion in 2020 and projected to reach US$31.9 Billion by 2027***
Revolution MD's near-term strategy is to submit the Pre-IND to the FDA and complete the device that will be used for clinical trials. Upon the completion of the near-term strategy the company intends to evaluate a publicly listing, and strategic alliances with key players in the medical device and pharmaceutical sectors.
Our Team has an Outstanding Track Record | Revolution MD is supported by a world-class team of experts in pharmaceutical, regulatory, healthcare, cyber security, and finance industries, including Igor Gonda, former Pharma CEO, who successfully developed an opioid inhaler and navigated clinical trials.